Your search results.

05 December 2012 Apexigen

"We are very pleased to partner with Apexigen in the manufacture of one of their pipeline antibodies," said Simon Sturge, Boehringer Ingelheim's Senior Vice President Biopharmaceuticals. "In particular, this is an exciting project for Boehringer Ingelheim.

• Size: 7 kB
• Last Update: 5.12.2012

Christian Boehringer

• Size: 2 MB
• Last Update: 3.12.2012

Argentina

• Size: 1 kB
• Last Update: 14.12.2012

Argentina

Boehringer Ingelheim, headquarterd in Germany, is a global business speard around the world, manufacturing and marketing pharmaceuticals, biopharmaceuticals, pharma chemicals and animal health products.

• Size: 3 kB
• Last Update: 14.12.2012

10 December 2012 Oncology

Boehringer Ingelheim to initiate Phase III study in leukaemia with its compound volasertib* based on positive Phase II results

• Size: 16 kB
• Last Update: 10.12.2012

10 December 2012 Dabigatran

Treatment with Pradaxa® associated with better patient outcomes after a major bleeding event compared to warfarin

• Size: 21 kB
• Last Update: 11.12.2012

Recommend Confirmation

Many Thanks Your recommendation has been sent. Useful Links Jobs opportunities Our products Partnerships & licensing opportunities Boehringer Ingelheim worldwide Boehringer Ingelheim in the USA Disclaimers Terms of use

• Size: 3 kB
• Last Update: 20.11.2012

Discovering Together

• Size: 4 kB
• Last Update: 20.11.2012

16 November 2010 BIBF1120

Ingelheim, Germany, 16 November 2010 – New data presented at the 16 th International Colloquium on Lung and Airway Fibrosis (ICLAF) show that Boehringer Ingelheim’s investigational compound BIBF1120, a triple kinase inhibitor, may provide significant clinical benefit in patients with idiopathic

• Size: 11 kB
• Last Update: 5.11.2012